(Q51531803)

English

Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia.

scientific article published in October 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. (English)

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

1 reference

based on heuristic

inferred from title

author name string

Taner Damci

1

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Serkan Tatliagac

2

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Zeynep Osar

3

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Hasan Ilkova

4

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

publication date

1 October 2003

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

European Journal of Internal Medicine

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

14

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

6

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

357-360

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent reductions of serum leptin and lipids during weight loss in obese men with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system control of food intake

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between free fatty acids and glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bezafibrate reduces blood glucose in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent hypoglycaemic episodes in a patient with Type 2 diabetes under fibrate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation

1 reference

https://api.crossref.org/works/10.1016%2FS0953-6205%2803%2990001-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0953-6205(03)90001-X

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

1 reference

Europe PubMed Central

6 April 2018

http://europepmc.org/abstract/MED/14769493

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51531803&oldid=2070097413"